Unilife is a U.S. based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for our products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. All of our syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. We are ISO 13485 certified and have FDA-registered medical device manufacturing facilities in Pennsylvania.
Our main product is the UnifillTM ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines. We have a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill syringe and is funding our industrialization program. In addition, we have retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.
News & Events
Jefferies titles report “Aces in Hand: Commercial Deal Flow Appears Imminent” Jefferies analyst Raj Denhoy highlights Unilife’s “bigger stories are the EZMix and Unifill deals which are forecasted to drive meaningful revenue come F14. They reiterated their Buy Rating & $3.50 target “as the story transitions into
YORK, Pa., May 9, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended March 31, 2013, (the third quarter of Fiscal Year 2013). Recent Highlights In April, Unilif
Schedules Conference Call for 4:30 p.m. EDT on Thursday, May 9, 2013 YORK, Pa., April 22, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) announced today that it intends to release its financial results for the fiscal 2013 third quarter ended March 31, 2013 after market trading ends
YORK, Pa., April 18, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today announced the development of the Unifill Assure™, a customized device from its Unifill® platform of ready-to-fill (prefilled) syringes that is designed to address unmet market needs for the injection of high